BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol 2013;59:897-903. [PMID: 23714157 DOI: 10.1016/j.jhep.2013.05.031] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Darvishi M, Tosan F, Nakhaei P, Manjili DA, Kharkouei SA, Alizadeh A, Ilkhani S, Khalafi F, Zadeh FA, Shafagh SG. Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathol Res Pract 2023;241:154241. [PMID: 36543080 DOI: 10.1016/j.prp.2022.154241] [Reference Citation Analysis]
2 Wirsching S, Fichter M, Cacicedo ML, Landfester K, Gehring S. Modification of Regulatory T Cell Epitopes Promotes Effector T Cell Responses to Aspartyl/Asparaginyl β-Hydroxylase. IJMS 2022;23:12444. [DOI: 10.3390/ijms232012444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157 [DOI: 10.4254/wjh.v14.i1.140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mangla B, Kumar P, Goyal K, Kohli K, Jindal S. Product development and scale-up challenges in cancer vaccine development. Nanotherapeutics in Cancer Vaccination and Challenges 2022. [DOI: 10.1016/b978-0-12-823686-4.00021-5] [Reference Citation Analysis]
5 Fan Y, Sun Y, Man C, Lang Y. Preoperative Serum Prealbumin Level and Adverse Prognosis in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis. Front Oncol 2021;11:775425. [PMID: 34746015 DOI: 10.3389/fonc.2021.775425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Chen H, Wang J, Zeng R, Luo Y, Guo K, Wu H, Yang Q, Jiang R, Sha W, Zhuo Z. Development and Validation of a Novel Mitophagy-Related Gene Prognostic Signature for Hepatocellular Carcinoma Based on Immunoscore Classification of Tumor. J Oncol 2021;2021:5070099. [PMID: 34733329 DOI: 10.1155/2021/5070099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Huang J, Zhang L, Chen J, Wan D, Zhou L, Zheng S, Qiao Y. The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma. Front Oncol 2021;11:744951. [PMID: 34650926 DOI: 10.3389/fonc.2021.744951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Liu S, Xu Z, Fang Z, Zhang D, Qin Z, Fan L, Duan J, Yin H, Zhang Y, Pang Q, Tan Y. The Combination of Age, International Standardized Ratio, Albumin and γ-Glutamyl Transpeptidase (AIAG), Tumor Size and Alpha Fetoprotein (AFP) Stage as the Prognostic Model for Hepatitis B-Related Hepatocellular Carcinoma. Int J Gen Med 2021;14:4291-301. [PMID: 34408472 DOI: 10.2147/IJGM.S323293] [Reference Citation Analysis]
9 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
11 Chen J, Ding Y, Huang F, Lan R, Wang Z, Huang W, Chen R, Wu B, Fu L, Yang Y, Liu J, Hong J, Zhang W, Zhang L. Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells. Oncol Lett 2021;21:409. [PMID: 33841570 DOI: 10.3892/ol.2021.12670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Pan Z, Liu C, Zhi Y, Xie Z, Wu L, Jiang M, Zhang Y, Zhou R, Zhao L. LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. Oncogene 2021;40:2581-95. [PMID: 33686242 DOI: 10.1038/s41388-021-01736-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep 2021;11:4493. [PMID: 33627697 DOI: 10.1038/s41598-021-83868-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Yang L, Hao X, Hu X, Wang Z, Yang K, Mi Y, Yang Y, Xu H, Yang G, Wang Y. Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. Thorac Cancer 2020;11:3501-9. [PMID: 33075201 DOI: 10.1111/1759-7714.13689] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Fan Y, Gu X, Gao Z. Prognostic value of C-reactive protein to albumin ratio in patients with hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol 2020;44:241-3. [PMID: 31444039 DOI: 10.1016/j.clinre.2019.07.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Abdel Ghafar MT, Morad MA, El-Zamarany EA, Ziada D, Soliman H, Abd-Elsalam S, Salama M. Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study. Int Immunopharmacol 2020;82:106375. [PMID: 32169808 DOI: 10.1016/j.intimp.2020.106375] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
18 Corrao G, Marvaso G, Ferrara R, Lo Russo G, Gugliandolo SG, Piperno G, Spaggiari L, De Marinis F, Orecchia R, Garassino MC, Jereczek-Fossa BA. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer 2020;142:70-9. [PMID: 32120227 DOI: 10.1016/j.lungcan.2020.02.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hu CL, Du QC, Wang ZX, Pang MQ, Wang YY, Li YY, Zhou Y, Wang HJ, Fan HN. Relationship between platelet-based models and the prognosis of patients with malignant hepatic tumors. Oncol Lett 2020;19:2384-96. [PMID: 32194738 DOI: 10.3892/ol.2020.11317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Momeni Roudsari N, Lashgari N, Momtaz S, Abdolghaffari AH. Hepatobiliary Tumors: Immunopathology and Immunotherapy. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_9] [Reference Citation Analysis]
21 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
22 Löffler MW, Nussbaum B, Jäger G, Jurmeister PS, Budczies J, Pereira PL, Clasen S, Kowalewski DJ, Mühlenbruch L, Königsrainer I, Beckert S, Ladurner R, Wagner S, Bullinger F, Gross TH, Schroeder C, Sipos B, Königsrainer A, Stevanović S, Denkert C, Rammensee HG, Gouttefangeas C, Haen SP. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. Front Immunol 2019;10:2526. [PMID: 31803175 DOI: 10.3389/fimmu.2019.02526] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
23 Chen J, Gao G, Wang H, Ye X, Zhou J, Lin J. Expression and clinical significance of latent-transforming growth factor beta-binding protein 2 in primary hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e17216. [PMID: 31574831 DOI: 10.1097/MD.0000000000017216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Du QC, Hu CL, Wang YY, Zhou Y. Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy. Acta Cir Bras 2019;34:e201900710. [PMID: 31531530 DOI: 10.1590/s0102-865020190070000010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci 2019;76:4869-86. [PMID: 31377844 DOI: 10.1007/s00018-019-03255-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]
26 Fountzilas C, Lee SS, Iyer RV, Boland PM. Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. Immune Checkpoint Inhibitors in Cancer 2019. [DOI: 10.1016/b978-0-323-54948-6.00004-4] [Reference Citation Analysis]
27 Petrizzo A, Tagliamonte M, Mauriello A, Costa V, Aprile M, Esposito R, Caporale A, Luciano A, Arra C, Tornesello ML, Buonaguro FM, Buonaguro L. Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018;16:286. [PMID: 30340600 DOI: 10.1186/s12967-018-1662-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
28 Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, Wang X, Liu T, Li YM. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis. Cytotherapy 2018;20:975-89. [PMID: 30072299 DOI: 10.1016/j.jcyt.2018.06.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
29 Tagliamonte M, Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Buonaguro L. Potentiating cancer vaccine efficacy in liver cancer. Oncoimmunology 2018;7:e1488564. [PMID: 30288355 DOI: 10.1080/2162402X.2018.1488564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
30 Russo FP, Imondi A, Lynch EN, Farinati F. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis 2018;50:640-6. [PMID: 29636240 DOI: 10.1016/j.dld.2018.03.014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
31 Gu L, Wen W, Wu Z, Bai K, Liu W, Lai G, Li D. Abnormal platelet count correlates with poor survival in hepatocellular carcinoma. Infection International 2018;6:93-102. [DOI: 10.1515/ii-2017-0160] [Reference Citation Analysis]
32 Xie Y, Xiang Y, Sheng J, Zhang D, Yao X, Yang Y, Zhang X. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. J Immunol Res 2018;2018:8740976. [PMID: 29785403 DOI: 10.1155/2018/8740976] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
33 Lee S, Loecher M, Iyer R. Immunomodulation in hepatocellular cancer. J Gastrointest Oncol. 2018;9:208-219. [PMID: 29564186 DOI: 10.21037/jgo.2017.06.08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
34 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
35 Wang Y, Yang X, Yu Y, Xu Z, Sun Y, Liu H, Cheng J, Liu M, Sha B, Li L, Ding N, Li Z, Jin H, Qian Q. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells. J Cancer 2018;9:275-87. [PMID: 29344274 DOI: 10.7150/jca.22176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
36 Pang Q, Zhou L, Qu K, Cui RX, Jin H, Liu HC. Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study. Eur J Gastroenterol Hepatol 2018;30:60-70. [PMID: 29189392 DOI: 10.1097/MEG.0000000000001021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
37 Han Q, Wang Y, Pang M, Zhang J. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC. J Exp Clin Cancer Res. 2017;36:156. [PMID: 29115974 DOI: 10.1186/s13046-017-0623-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
38 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
39 Yu Y, Song J, Zhang R, Liu Z, Li Q, Shi Y, Chen Y, Chen J. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma. Oncotarget. 2017;8:79722-79730. [PMID: 29108352 DOI: 10.18632/oncotarget.19178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
40 Zhang Q, Yuan XF, Lu Y, Li ZZ, Bao SQ, Zhang XL, Yang YY, Fan DM, Zhang YZ, Wu CX, Guo HX, Zhang YJ, Ye Z, Xiong DS. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells. Int J Cancer 2017;141:1445-57. [PMID: 28643325 DOI: 10.1002/ijc.30846] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
41 Buonaguro L; HEPAVAC Consortium. New vaccination strategies in liver cancer. Cytokine Growth Factor Rev 2017;36:125-9. [PMID: 28688773 DOI: 10.1016/j.cytogfr.2017.06.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
42 Wang C, Yang Y, Sun D, Jiang Y. Prognosis of hepatocellular carcinoma patients with bile duct tumor thrombus after hepatic resection or liver transplantation in Asian populations: A meta-analysis. PLoS One 2017;12:e0176827. [PMID: 28472122 DOI: 10.1371/journal.pone.0176827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
43 Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. Vaccine Approaches in Hepatocellular Carcinoma. Immunotherapy of Hepatocellular Carcinoma 2017. [DOI: 10.1007/978-3-319-64958-0_1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res 2017;27:59-73. [PMID: 28008927 DOI: 10.1038/cr.2016.153] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 10.9] [Reference Citation Analysis]
45 Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, Hodi FS, Awad MM. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 2016;4:84. [PMID: 28018599 DOI: 10.1186/s40425-016-0193-2] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 10.6] [Reference Citation Analysis]
46 Buonaguro FM, Buonaguro L. Cancer vaccines for hepatocellular carcinoma: future directions. Immunotherapy 2016;8:391-3. [PMID: 26973120 DOI: 10.2217/imt-2015-0018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
47 Ascierto PA, Cartenì G, Gridelli C, Pignata S, Pinto A, Criscitiello C, Buonaguro L, Pepe S, Mabilia R, Montesarchio V, Daniele B, De Placido S. What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). j immunotherapy cancer 2016;4:41. [DOI: 10.1186/s40425-016-0144-y] [Reference Citation Analysis]
48 Petrizzo A, Buonaguro L. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. J Immunother Cancer. 2016;4:71. [PMID: 27879973 DOI: 10.1186/s40425-016-0182-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
49 Zhang Z, Zhang Y, Wang W, Hua Y, Liu L, Shen S, Peng B. Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. J Surg Res. 2017;210:99-107. [PMID: 28457347 DOI: 10.1016/j.jss.2016.11.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
50 Fu S, Zhou RR, Li N, Huang Y, Fan XG. Hepatitis B virus X protein in liver tumor microenvironment. Tumour Biol. 2016; Epub ahead of print. [PMID: 27658781 DOI: 10.1007/s13277-016-5406-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
51 Petrizzo A, Caruso FP, Tagliamonte M, Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R, Ciliberto G, Buonaguro FM, Buonaguro L. Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Sci Rep 2016;6:29258. [PMID: 27387388 DOI: 10.1038/srep29258] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
52 Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM. Cellular prognostic markers in hepatocellular carcinoma. Future Oncol 2015;11:1591-8. [PMID: 26043213 DOI: 10.2217/fon.15.39] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
53 Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L. Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol 2016;39:103-13. [PMID: 26851637 DOI: 10.1016/j.coi.2016.01.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
54 Flecken T, Thimme R. Role of the Immune System in Hepatocellular Carcinoma: Implications for Existing and Novel Therapies. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_13] [Reference Citation Analysis]
55 Pang Q, Qu K, Zhang JY, Song SD, Liu SS, Tai MH, Liu HC, Liu C. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015;94:e1431. [PMID: 26376382 DOI: 10.1097/MD.0000000000001431] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
56 Pang Q, Bi JB, Xu XS, Liu SS, Zhang JY, Zhou YY, Qu K, Liu C. King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2015;27:1337-46. [PMID: 26275082 DOI: 10.1097/MEG.0000000000000452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
57 Pang Q, Qu K, Zhang J, Xu X, Liu S, Song S, Wang R, Zhang L, Wang Z, Liu C. Cigarette smoking increases the risk of mortality from liver cancer: A clinical-based cohort and meta-analysis. J Gastroenterol Hepatol 2015;30:1450-60. [PMID: 25967392 DOI: 10.1111/jgh.12990] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
58 Li J, Sun R, Yu Z, Liang H, Shen S, Kan Q. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells. Cancer Biotherapy and Radiopharmaceuticals 2015;30:336-41. [DOI: 10.1089/cbr.2015.1857] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
59 Zhang HM, Jiang WT, Pan C, Deng YL, Zheng H, Shen ZY. Milan criteria, University of California, San Francisco, criteria, and model for end-stage liver disease score as predictors of salvage liver transplantation. Transplant Proc 2015;47:438-44. [PMID: 25769587 DOI: 10.1016/j.transproceed.2014.10.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
60 Pang Q, Qu K, Bi JB, Liu SS, Zhang JY, Song SD, Lin T, Xu XS, Wan Y, Tai MH, Liu HC, Dong YF, Liu C. Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis. World J Gastroenterol 2015; 21(25): 7895-7906 [PMID: 26167090 DOI: 10.3748/wjg.v21.i25.7895] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
61 Buonaguro L; HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother 2016;65:93-9. [PMID: 26093657 DOI: 10.1007/s00262-015-1728-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
62 Pang Q, Zhang JY, Xu XS, Song SD, Qu K, Chen W, Zhou YY, Miao RC, Liu SS, Dong YF, Liu C. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence. World J Gastroenterol 2015; 21(18): 5607-5621 [PMID: 25987786 DOI: 10.3748/wjg.v21.i18.5607] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
63 Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, Buonaguro L. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunol Immunother 2015;64:1305-14. [DOI: 10.1007/s00262-015-1698-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
64 He Y, Hong Y, Mizejewski GJ. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy 2014;6:725-36. [PMID: 25041030 DOI: 10.2217/imt.14.46] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
65 Pang Q, Zhang JY, Xu XS, Song SD, Chen W, Zhou YY, Miao RC, Qu K, Liu SS, Dong YF, Liu C. The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma. Scand J Clin Lab Invest 2015;75:73-84. [PMID: 25465804 DOI: 10.3109/00365513.2014.981759] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
66 Lu L, Yan H, Shyam-Sundar V, Janowitz T. Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther 2014;8:1539-53. [PMID: 25302014 DOI: 10.2147/DDDT.S65963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
67 Xu Q, Liu X, Zheng X, Yao Y, Liu Q. PKM2 regulates Gli1 expression in hepatocellular carcinoma. Oncol Lett 2014;8:1973-9. [PMID: 25289083 DOI: 10.3892/ol.2014.2441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
68 Aref AM, Hoa NT, Ge L, Agrawal A, Dacosta-Iyer M, Lambrecht N, Ouyang Y, Cornforth AN, Jadus MR. HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma. Onco Targets Ther. 2014;7:1061-1070. [PMID: 24966688 DOI: 10.2147/ott.s61442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]